Trial Profile
Phase I study of Treprostinil (LIQ-861) in healthy volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Jan 2018
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Liquidia Technologies
- 25 Jan 2018 According to the Liquidia Technologies media release, results from this trial were presented at the 12th Pulmonary Vascular Research Institute (PVRI) Annual World Congress on Pulmonary Vascular Disease.
- 25 Jan 2018 Results presented in a Liquidia Technologies media release.
- 10 Jan 2018 New trial record